TNF and breast cancer: In preclinical studies, MV-s-NAP demonstrated improved efficacy over the MV alone, doubling the survival time in mouse models of BC and increasing the levels of certain cytokines like TNFα, IL-6, and IL-12/23 in the pleural effusion.